Literature DB >> 16620146

Triflusal: a review of its use in cerebral infarction and myocardial infarction, and as thromboprophylaxis in atrial fibrillation.

David Murdoch1, Greg L Plosker.   

Abstract

Triflusal (Aflen, Disgren, Tecnosal, Triflux) is a novel platelet antiaggregant with structural similarities to salicylates, but which is not derived from aspirin. It has similar efficacy to aspirin in patients with cerebral or myocardial infarction, but has a reduced risk of haemorrhagic complications. In addition, triflusal plus moderate-intensity anticoagulation has demonstrated efficacy when used as thromboprophylaxis in atrial fibrillation. As such, triflusal has a role in the primary prevention of cerebrovascular events in atrial fibrillation, and for the secondary prevention of cerebral and myocardial infarction, primarily as an alternative to aspirin in patients for whom aspirin is unsuitable.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16620146     DOI： 10.2165/00003495-200666050-00009

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  60 in total

1.  Can aspirin ever be surpassed for stroke prevention?

Authors:  David C Tong
Journal:  Stroke       Date:  2003-04       Impact factor: 7.914

2.  European Stroke Initiative Recommendations for Stroke Management-update 2003.

Authors:  Tom Skyhoj Olsen; Peter Langhorne; Hans Christoph Diener; Michael Hennerici; Jose Ferro; Johani Sivenius; Nils Gunnar Wahlgren; Philip Bath
Journal:  Cerebrovasc Dis       Date:  2003       Impact factor: 2.762

3.  Interaction between a rat model of cerebral ischemia and beta-amyloid toxicity: inflammatory responses.

Authors:  Shawn N Whitehead; Vladimir C Hachinski; David F Cechetto
Journal:  Stroke       Date:  2004-12-09       Impact factor: 7.914

4.  Effect of triflusal and other salicylic acid derivatives on cyclic AMP levels in rat platelets.

Authors:  J García-Rafanell; J Ramis; L Gomez; J Forn
Journal:  Arch Int Pharmacodyn Ther       Date:  1986-11

Review 5.  Antithrombotic and thrombolytic therapy for ischemic stroke: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy.

Authors:  Gregory W Albers; Pierre Amarenco; J Donald Easton; Ralph L Sacco; Philip Teal
Journal:  Chest       Date:  2004-09       Impact factor: 9.410

6.  Protective effect of triflusal against acute myocardial infarction in patients with unstable angina: results of a Spanish multicenter trial. Grupo de Estudio del Triflusal en la Angina Inestable.

Authors:  L Plaza; L López-Bescós; L Martín-Jadraque; E Alegría; J M Cruz-Fernández; J Velasco; J A Ruipérez; F Malpartida; A Artal; A Cabadés
Journal:  Cardiology       Date:  1993       Impact factor: 1.869

7.  High risk of thromboemboli early after bioprosthetic cardiac valve replacement.

Authors:  M Heras; J H Chesebro; V Fuster; W J Penny; D E Grill; K R Bailey; G K Danielson; T A Orszulak; J R Pluth; F J Puga
Journal:  J Am Coll Cardiol       Date:  1995-04       Impact factor: 24.094

Review 8.  Triflusal.

Authors:  W McNeely; K L Goa
Journal:  Drugs       Date:  1998-06       Impact factor: 9.546

9.  Effects of triflusal and its main metabolite HTB on platelet interaction with subendothelium in healthy volunteers.

Authors:  J P De La Cruz; M A Villalobos; P J García; J M Smith-Agreda; F Sánchez de la Cuesta
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

10.  Guidelines for percutaneous coronary interventions. The Task Force for Percutaneous Coronary Interventions of the European Society of Cardiology.

Authors:  Sigmund Silber; Per Albertsson; Francisco F Avilés; Paolo G Camici; Antonio Colombo; Christian Hamm; Erik Jørgensen; Jean Marco; Jan-Erik Nordrehaug; Witold Ruzyllo; Philip Urban; Gregg W Stone; William Wijns
Journal:  Eur Heart J       Date:  2005-03-15       Impact factor: 29.983
View more
  9 in total

1.  Gastrointestinal safety of triflusal solution in healthy volunteers: a proof of concept endoscopic study.

Authors:  Rosa M Antonijoan; Ignasi Gich; Analia Azaro; Sergio Sainz; Joaquim Balanzó; Iñaki Izquierdo; Javier Borja; Esther Donado; Iris Blanch; Manel J Barbanoj
Journal:  Eur J Clin Pharmacol       Date:  2011-02-16       Impact factor: 2.953

2.  Triflusal reduces dense-core plaque load, associated axonal alterations and inflammatory changes, and rescues cognition in a transgenic mouse model of Alzheimer's disease.

Authors:  M Coma; L Serenó; B Da Rocha-Souto; T C Scotton; J España; M B Sánchez; M Rodríguez; J Agulló; C Guardia-Laguarta; M Garcia-Alloza; L A Borrelli; J Clarimón; A Lleó; B J Bacskai; C A Saura; B T Hyman; T Gómez-Isla
Journal:  Neurobiol Dis       Date:  2010-02-10       Impact factor: 5.996

Review 3.  Antiplatelet drugs--do we need new options? With a reappraisal of direct thromboxane inhibitors.

Authors:  Sergio Coccheri
Journal:  Drugs       Date:  2010-05-07       Impact factor: 9.546

Review 4.  Update on antiplatelet agents, including MATCH, CHARISMA, and ESPRIT.

Authors:  Maryna Skliut; Dara G Jamieson
Journal:  Curr Cardiol Rep       Date:  2008-02       Impact factor: 2.931

5.  Population pharmacokinetic and pharmacodynamic modeling of transformed binary effect data of triflusal in healthy Korean male volunteers: a randomized, open-label, multiple dose, crossover study.

Authors:  Sung Min Park; Joomi Lee; Sook Jin Seong; Jong Gwang Park; Mi-Ri Gwon; Mi-sun Lim; Hae Won Lee; Young-Ran Yoon; Dong Heon Yang; Kwang-Il Kwon; Seunghoon Han
Journal:  BMC Pharmacol Toxicol       Date:  2014-12-23       Impact factor: 2.483

Review 6.  Drug repositioning and repurposing for Alzheimer disease.

Authors:  Clive Ballard; Dag Aarsland; Jeffrey Cummings; John O'Brien; Roger Mills; Jose Luis Molinuevo; Tormod Fladby; Gareth Williams; Pat Doherty; Anne Corbett; Janet Sultana
Journal:  Nat Rev Neurol       Date:  2020-09-16       Impact factor: 42.937

7.  Effect of premedication method and drug resistance of antiplatelet agent on periprocedural thromboembolic events during coil embolization of an unruptured intracranial aneurysm.

Authors:  Se Hwan Park; Yong Bae Kim; Seung Kon Huh
Journal:  J Cerebrovasc Endovasc Neurosurg       Date:  2012-09-28

8.  Effect of Triflusal on Primary Vascular Dysregulation Compared with Aspirin: A Double-Blind, Randomized, Crossover Trial.

Authors:  Sanghoon Shin; Kwang-Joon Kim; In-Jeong Cho; Geu-Ru Hong; Yangsoo Jang; Namsik Chung; Young Min Rah; Hyuk-Jae Chang
Journal:  Yonsei Med J       Date:  2015-09       Impact factor: 2.759

9.  2-Hydroxy-4-Methylbenzoic Anhydride Inhibits Neuroinflammation in Cellular and Experimental Animal Models of Parkinson's Disease.

Authors:  Soo-Yeol Song; In-Su Kim; Sushruta Koppula; Ju-Young Park; Byung-Wook Kim; Sung-Hwa Yoon; Dong-Kug Choi
Journal:  Int J Mol Sci       Date:  2020-11-02       Impact factor: 5.923
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.